Year All20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 06, 2023 Read More BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 03, 2023 Read More BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 26, 2023 Read More BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe Jan 23, 2023 Read More BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance Jan 09, 2023 Read More BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 09, 2023 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 05, 2023 Read More BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference Jan 04, 2023 Read More
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 03, 2023 Read More
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 26, 2023 Read More
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe Jan 23, 2023 Read More
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance Jan 09, 2023 Read More
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 09, 2023 Read More